The relatively hypothetical risk of worsening COVID-19 does not justify discontinuing or switching ARBs or ACE inhibitors due to the specific risk of destabilizing blood pressure control, stroke, heart attack, or worsening heart failure (van der Wardt et al. 2017; Halliday et al. 2019). Here, ACE is linked to COVID-19.